A question from biology.
A company built to pursue it.

From understanding translation
to engineering possibility.

KritRNA begins with a question at the heart of translation biology: when a genetic message stops too early, what determines whether the cell can be helped to read through it?

Dr. Nikhil Bharti’s research in molecular biology, including work in the University of Hamburg’s translation-biology environment, brought that question into focus. His co-first-authored 2024 Nature Communications study examined how the translation velocity upstream of a premature stop influences engineered suppressor-tRNA performance.

That research motivates a practical ambition: connect molecular design with the context in which a molecule must work. KritRNA is developing a platform to help turn that ambition into experimentally testable candidate choices—not to treat a computational score as a therapeutic result.

Nikhil and Pragati Bhaisora are building that capability from India as co-founders and directors. Nikhil leads the scientific and computational direction. Pragati leads outreach, awareness and community engagement, connecting a technically demanding programme with the people and relationships that give it purpose.

Academic research and company development are distinct. Institutional affiliations identify research experience, not institutional endorsement or ownership by KritRNA of university intellectual property.